Trial Profile
A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs RG 7882 (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genentech
- 18 Oct 2021 Status has been changed from completed to discontinued, as per Results published in the Gynecologic Oncology
- 06 Oct 2021 Results published in the Gynecologic Oncology
- 16 Mar 2019 Results assessing the pharmacokinetics of Dmuc4064a (anti-MUC16 thiomab drug conjugate; three PK analytes-antibody- conjugated MMAE (acMMAE), total antibody (tAb), and unconjugated MMAE)) in patients with platinum-resistant ovarian cancer, were presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.